Literature DB >> 9822539

Synthesis and evaluation of 11beta-substituted 21-chloro/iodo-(17alpha,20E/Z)-19-norpregna-1,3,5(10),20-te traene-3, 17beta-diols: high-affinity ligands for the estrogen receptor.

R N Hanson1, E Napolitano, R Fiaschi.   

Abstract

We have synthesized six new estrogens substituted at the 11beta-position with a methoxy or vinyl group and at the 17alpha-position with an (E)- or (Z)-chloro/iodovinyl moiety. The products were obtained in good overall yields from the corresponding tri-n-butylstannylvinyl intermediates using the electrophilic halodestannylation methodology. The six new ligands were compared to the 11beta-unsubstituted chloro/iodovinyl derivatives and the 11beta-methoxy (E)- and (Z)-iodovinyl estrogens to evaluate the effects of 11beta-substitution and 20E/Z-stereochemistry. While all the compounds exhibited high affinity for the estrogen receptor, the 20Z-isomers demonstrated higher affinity than the corresponding 20E-isomers. In addition, the presence of the lipophilic 11beta-substituent was favored over either no substituent or a polar (methoxy) group. Within each isomeric series, the presence of the 21-halo substituent had different effects. For the 20E-series, the 21-chloro products had a higher affinity than the 21-iodo analogue, whereas for the 20Z-series the effect was reversed. These results provide additional insights into the interaction of substituted estradiols with the hormone binding domain of the estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822539     DOI: 10.1021/jm9801051

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells.

Authors:  Kinh-Luan Dao; Rupa R Sawant; J Adam Hendricks; Victoria Ronga; Vladimir P Torchilin; Robert N Hanson
Journal:  Bioconjug Chem       Date:  2012-04-04       Impact factor: 4.774

2.  Synthesis and evaluation of 17α-(dimethylphenyl)vinyl estradiols as probes of the estrogen receptor-α ligand binding domain.

Authors:  Robert N Hanson; Emmett McCaskill; Pakamas Tongcharoensirikul; Robert Dilis; David Labaree; Richard B Hochberg
Journal:  Steroids       Date:  2012-01-17       Impact factor: 2.668

3.  Targeting the estrogen receptor with metal-carbonyl derivatives of estradiol.

Authors:  Robert N Hanson; Rein Kirss; Emmett McCaskill; Edward Hua; Pakamas Tongcharoensirikul; Sandra L Olmsted; David Labaree; Richard B Hochberg
Journal:  Bioorg Med Chem Lett       Date:  2012-01-08       Impact factor: 2.823

4.  Synthesis and evaluation of 11β-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists.

Authors:  Robert N Hanson; Edward Hua; J Adam Hendricks; David Labaree; Richard B Hochberg
Journal:  Bioorg Med Chem       Date:  2012-05-07       Impact factor: 3.641

5.  Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry.

Authors:  Robert N Hanson; Edward Hua; David Labaree; Richard B Hochberg; Kyle Proffitt; John M Essigmann; Robert G Croy
Journal:  Org Biomol Chem       Date:  2012-09-25       Impact factor: 3.876

6.  Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.

Authors:  Chinnasamy Ramesh; Tapan K Nayak; Ritwik Burai; Megan K Dennis; Helen J Hathaway; Larry A Sklar; Eric R Prossnitz; Jeffrey B Arterburn
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

7.  Potential activity of fevicordin-A from Phaleria macrocarpa (Scheff) Boerl. seeds as estrogen receptor antagonist based on cytotoxicity and molecular modelling studies.

Authors:  Muchtaridi Muchtaridi; Muhammad Yusuf; Ajeng Diantini; Sy Bing Choi; Belal O Al-Najjar; Jerry V Manurung; Anas Subarnas; Tri H Achmad; Savitri R Wardhani; Habibah A Wahab
Journal:  Int J Mol Sci       Date:  2014-04-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.